DSM-Firmenich AG (DSFIRN) Stock Price & Analysis
DSFIRN Stock Chart & Stats
- Day’s Range
- MXN 1,301.79 - MXN 1,301.79
- 52-Week Range
- MXN 1,301.79 - MXN 2,528.25
- Previous Close
- MXN 1,301.79
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 536.32B
- Enterprise Value
- MXN 25.37B
- Total Cash (Recent Filing)
- MXN 2.31B
- Total Debt (Recent Filing)
- MXN 6.76B
- Price to Earnings (P/E)
- ―
- Beta
- 0.18
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 29.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.86%
Bulls Say, Bears Say
Bulls Say
Revenue Recovery And Gross-Margin Improvement
The strong revenue rebound indicates renewed demand across the business, while higher gross margin suggests improved pricing, mix, or cost control. Together, these trends can strengthen operating leverage and support more durable earnings recovery if maintained over coming quarters.
Positive Cash Generation
Positive operating and free cash flow despite reported net losses demonstrates that the company is converting its operations into cash. This supports ongoing investment, debt servicing, and resilience during the earnings recovery, although the durability of conversion remains important.
Diversified Specialty-Ingredient Business Model
Exposure to multiple consumer and industrial end markets reduces reliance on any single application and broadens the addressable opportunity. Science-based formulations, application expertise, and recurring customer purchases can reinforce relationships and support repeat demand.
Bears Say
Persistent Net Losses
Sustained net losses weaken confidence that recent revenue improvement will translate into durable shareholder earnings. They also limit internal capital generation from profits and leave the company more dependent on operational improvements before returns can normalize.
Volatile And Weaker Operating Profitability
The decline in operating margin and reversal from earlier profits indicate that earnings quality remains unsettled despite better gross margin. Continued volatility makes it harder to assess sustainable operating leverage and increases execution risk during the recovery.
Negative Returns Despite Rising Leverage
Leverage remains moderate, but its upward direction matters more because capital is currently producing negative returns. If losses persist, higher debt can reduce financial flexibility and increase the pressure on management to restore profitability and improve capital efficiency.
DSM-Firmenich AG News
DSFIRN FAQ
What was DSM-Firmenich AG’s price range in the past 12 months?
What is DSM-Firmenich AG’s market cap?
When is DSM-Firmenich AG’s upcoming earnings report date?
How were DSM-Firmenich AG’s earnings last quarter?
Is DSM-Firmenich AG overvalued?
Does DSM-Firmenich AG pay dividends?
What is DSM-Firmenich AG’s EPS estimate?
How many shares outstanding does DSM-Firmenich AG have?
What happened to DSM-Firmenich AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of DSM-Firmenich AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
- Sector
- General
- Industry
- Chemicals - Specialty
- CEO
- Dimitri de Vreeze
- Employees
- 28,550
- Website
- www.dsm-firmenich.com
- Address
- Wurmisweg 576, Kaiseraugst, AG, 4303, CH
DSM-Firmenich AG (DSFIRN) Earnings & Revenues
DSFIRN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 1 | 10 |
| Technical Analysis | 4 | 1 | 1 |
| Moving Averages | 3 | 0 | 9 |






